Health Catalyst Stock Zacks

Health Catalyst Stock Zacks. Other research analysts have also recently issued reports about the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock.

University of Maryland CIO Joins Health Catalyst as Senior from www.prnewswire.com

Since then, hcat shares have increased by 10.1% and is now trading at $30.36. Health catalyst is a zacks rank #2 (buy) that sports an f for value and b for growth. The consensus price target hints at a 33.3% upside potential for catalyst (cprx).

Source: mayfieldrecorder.com

Health catalyst (nasdaq:hcat) was downgraded by zacks investment research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on tuesday, zacks.com. 387792 shares of the stock traded hands, compared to its average volume of 414928.

Source: www.marketbeat.com

Zacks investment research cut health catalyst from a “buy” rating to a “hold” rating in a research report on tuesday, january 11th. The company also provides its revenue guidance for 2022.

Source: www.zacks.com

Is a provider of data and analytics technology and services to healthcare organizations. Health catalyst, which belongs to the zacks medical info systems industry, posted revenues of $59.63 million for the quarter ended june 2021, surpassing the zacks consensus estimate by 5.20%.

Source: www.prnewswire.com

The company has topped consensus revenue estimates four times over the last four quarters. Zacks investment research cut shares of health catalyst from a buy rating to a hold rating in a research report on tuesday, january 11th.

Source: mayfieldrecorder.com

And changed its name to health catalyst, inc. Zacks investment research lowered shares of health catalyst from a “buy” rating to a “hold” rating in a research note on tuesday, january 11th.

The Company Has Topped Consensus Revenue Estimates Four Times Over The Last Four Quarters.

Finally, zacks investment research downgraded health catalyst from a buy rating to a hold rating in a research note on tuesday, january 11th. Zacks investment research cut health catalyst from a “buy” rating to a “hold” rating in a research report on tuesday, january 11th. Jefferies financial group started coverage on shares of health catalyst in a research report on wednesday, december 1st.

Health Catalyst (Nasdaq:hcat) Was Downgraded By Zacks Investment Research From A Buy Rating To A Hold Rating In A Report Released On Tuesday, Zacks.com Reports.

I love to see that growth divergence with a strong. Health catalyst's stock was trading at $27.58 on march 11th, 2020 when coronavirus reached pandemic status according to the world health organization. Zacks investment research lowered shares of health catalyst from a “buy” rating to a “hold” rating in a research note on tuesday, january 11th.

One Research Analyst Has Rated The Stock With A Hold Rating, Ten Have Issued A Buy Rating And One Has Issued A Strong Buy Rating To The Stock.

In a note to investors, the firm issued a new rating of buy. Health catalyst (nasdaq:hcat) was upgraded by zacks investment research from a hold rating to a buy rating in a research note issued to investors on wednesday, zacks.com reports. Finally, zacks investment research raised health catalyst from a hold rating to a buy rating and set a $45.00 price target on the stock in a research note on wednesday.

The Firm Currently Has A $45.00 Price Objective On The Stock.

Health catalyst, which belongs to the zacks medical info systems industry, posted revenues of $61.74 million for the quarter ended september 2021, surpassing the zacks consensus estimate by 1.29%. The analysts previously had rating of hold. Catalyst currently carries a zacks rank #4 (sell).

Health Catalyst, Which Belongs To The Zacks Medical Info Systems Industry, Posted Revenues Of $61.74 Million For The Quarter Ended September 2021, Surpassing The Zacks Consensus Estimate By 1.29%.

By zacks equity research published on december 14,2020. According to zacks, health catalyst inc. Other research analysts have also recently issued reports about the stock.